Effect of Palm Olein Intake on Lipid Profile and Fat Deposition
NCT ID: NCT02897674
Last Updated: 2019-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2016-02-29
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Palm Olein Intake on Lipid Profile and Appetite Regulation
NCT02924896
Blended Oil Beneficial for Blood Lipids Management
NCT03964857
Supplementation of Oil Palm Phenolics to Healthy Participants
NCT04164446
Effect of Dietary Fat Type in Combination With High Protein on Plasma Homocysteine Levels
NCT00941837
Effects of Supplementation With Linseed Oil on Blood Lipids in Vegetarians
NCT01788917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Population: 60 healthy males and females aged between 18 and 60 years, of which 30 participants with a BMI between 18.5-24.9kg/m2 and 30 participants with a BMI between 25-29.9kg/m2 and fasting plasma glucose and no evidence of insulin resistance will be recruited. No pre-existing morbidity including cardiac, hepatic or renal disease, history of diabetes, hypertension or hyperlipidemia.
Treatment: Pre-intervention: Participants will be asked to record habitual dietary intake by completion of a 4-day food diary and be asked to wear an accelerometer armband to assess physical activity at the beginning and at the end of supplementation period.
2 weeks standardization period: All participants will be asked to replace added fat in their diet with palm olein providing two thirds of 30% fat calories.
At the end of the standardization period, which will be the first day of a 12 week dietary intervention, as well as at the end of 12 week supplementation, participants will attend the clinical research facility for a study visit. Weight, height and waist circumference will be taken; total and regional body composition will be measured by MRI. Fasting and post prandial plasma glucose, insulin, appetite hormones and lipids will be measured. Participants will be asked to come in for follow-up visits at week 6 and 10 for a single blood samples and weight check.
12 week supplementation period: participants will be randomized into one of the three supplementation groups: palm olein, interesterified palm olein or soybean oil. Participants will be asked to consume two thirds of their 30%fat calories from one of the oils while incorporating it into their normal diet in cooking and baking.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal weight
Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
Palm olein
two thirds of the 30% fat calories will come from palm olein
Interesterified palm olein
two thirds of the 30% fat calories will come from interesterified palm olein
soybean oil
two thirds of the 30% fat calories will come from soybean oil
Overweight
Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
Palm olein
two thirds of the 30% fat calories will come from palm olein
Interesterified palm olein
two thirds of the 30% fat calories will come from interesterified palm olein
soybean oil
two thirds of the 30% fat calories will come from soybean oil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palm olein
two thirds of the 30% fat calories will come from palm olein
Interesterified palm olein
two thirds of the 30% fat calories will come from interesterified palm olein
soybean oil
two thirds of the 30% fat calories will come from soybean oil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Phase II: 30 healthy volunteers (male and female), of all ethnicities, aged 18-60 years, with a BMI of 25-29.9kg/m2.
Exclusion Criteria
* Abnormal liver function test (elevated alanine aminotransferase and aspartate transaminase)/ abnormal kidney function test (elevated plasma creatinine)
* History of type 2 diabetes mellitus, cancer, stomach ulcers, drug abuse or alcoholism, gastrointestinal disorders like Crohn's disease
* Smokers
* On lipid/blood pressure- lowering medication/supplements
* Blood pressure\>140/90 mm Hg
* Fasting total cholesterol \> 6.2 mmol/L
* Fasting triacylglyceride \> 2.0 mmol/L
* Candidates who are going abroad during the planned schedule for the dietary intervention
* Subject must not be allergic to intervention
* Pregnancy and breastfeeding (pregnancy test will be undertaken at the screening visit)
* Subjects taking nutritional supplements or on any weight-loss programs
* Subjects who gained or lost ≥ 3kg weight in the past three months
* Female subjects were not on oral contraceptives.
* Subjects with history of hypo- and hyperthyroidism
* Claustrophobia
* Metal implants for example cardiac pacemakers and join replacement
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Malaysia Palm Oil Board
OTHER_GOV
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary Frost
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NIHR/Wellcome Trust Imperial Clinical Research Facility
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Research Facility
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15HH2616
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.